Octaplasma® is a Health Canada licensed, standardized biopharmaceutical product.

It is manufactured to provide consistent levels of proteins, coagulation factors and inhibitor content1

Pathogen Inactivated to provide safety from known and emerging pathogens1

Low rate of allergic reactions and no documented TRALI 4

Standardized plasma protein levels in every bag3

Available without restrictions through Canadian Blood Services


Frequently Asked Questions

Browse through a list of FAQs

Click through →

How to Store and Administer

See the Product Monograph for complete storage, thawing and stability information.

Click through →

Clinical Evidence

Octaplasma® has been studied in both adults and children across a variety of clinical settings.

Click through →

For more information

Please see the Octaplasma Product Monograph for more information. If you have specific inquiries, please contact Octapharma Canada Inc.
Contact us

Resources &latest news

Indications and Important Safety Information for Octaplasma
Please see full prescribing information here
Indications and Usage

Complex deficiencies of coagulation factors such as consumption coagulopathy e.g. disseminated intravascular coagulation (DIC) or coagulopathy due to severe hepatic failure, massive transfusion, or repeated large volume plasma exchange (especially in patients with impaired liver function).

Octaplasma® may be used for emergency substitution therapy in coagulation factor deficiencies, when situations, e.g. haemorrhage, do not allow a precise laboratory diagnosis, or when a specific coagulation factor concentrate is not available.

Rapid reversal of effects of oral anticoagulants when vitamin K is insufficient in emergency situations, or in patients with impaired liver function.

Octaplasma is contraindicated in patients with IgA deficiency, with severe deficiency of protein S,and in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

Warnings and Precautions
This product is prepared from large pools of human plasma, which may contain the causative agents of hepatitis and other viral diseases. The physician should discuss the risks and benefits of this product with the patient before prescribing or administering to the patient.

Adverse Reactions
Anaphylactic reactions: In case of anaphylactic reaction or shock, the infusion must be stopped immediately. Treatment should follow the guidelines for shock therapy.

Risk of hypervolaemia, pulmonary oedema and/or cardiac failure with high dosages.

Increased risk of thromboembolic events in patients receiving large volumes of S/D treated plasma.
Risk of symptoms attributable to citrate toxicity with high infusion rates.

FFP: fresh frozen plasma; IgA: immunoglobulin A; S/D: solvent detergent; TRALI: transfusion-related acute lung injury.
* Clinical significance has not been established.
† Based on 2009–2021 PSUR data.

1. OctaplasmaTM Product Monograph, October 31 2022.

2. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion. 2000;40:84–90.

3. Heger A, Römisch J, Svae T-E. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white light treatment. Transfus Apher Sci. 2006;35:223–233.

4. Scully M, Longair I, Flynn M, Berryman J, Machin J. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang. 2007;93(2):154–158.

5. Ludlum CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006;367(9506):252–261.

6.Herraiz ALP. Emerging infectious disease and transfusion medicine: time to take action with proactive measures. Biomed J Scie & Tech Res. 2017;1(2): DOI: 10.26717/BJSTR.2017.01.000167.

7. Ludlam CA, Powderly WG, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006;367(9506):252-261.